TABLE 2.
Involvement of cannabinoid-activated receptors in the promigratory action of FAAH inhibitors and endocannabinoids
| Treatment groups | Migration (% Control) |
| Vehicle | 100.0 ± 21.1 |
| URB597 | 414.3 ± 27.0a |
| URB597 + AM-251 | 312.0 ± 43.0b |
| URB597 + AM-630 | 151.7 ± 20.3c |
| URB597 + AM-251 + AM-630 | 118.3 ± 12.4c |
| Vehicle | 100.0 ± 20.0 |
| AA-5HT | 599.3 ± 35.3a |
| AA-5HT + AM-251 | 486.7 ± 40.7b |
| AA-5HT + AM-630 | 272.7 ± 32.1c |
| AA-5HT + AM-251 + AM-630 | 92.7 ± 13.7c |
| Vehicle | 100.0 ± 5.8 |
| URB597 | 335.5 ± 56.4a |
| URB597 + Capsa | 51.3 ± 13.1c |
| AA-5HT | 454.5 ± 80.2a |
| AA-5HT + Capsa | 44.0 ± 13.6c |
| Capsa | 68.0 ± 4.0 |
| Vehicle | 100.0 ± 24.6 |
| AEA | 229.5 ± 30.5a |
| AEA + AM-251 | 180.3 ± 10.6b |
| AEA + AM-630 | 129.3 ± 8.5c |
| AEA + AM-251 + AM-630 | 127.8 ± 11.0c |
| AEA + Capsa | 95.0 ± 3.8c |
| Vehicle | 100.0 ± 9.1 |
| 2-AG | 240.3 ± 35.9a |
| 2-AG + AM-251 | 170.0 ± 19.2b |
| 2-AG + AM-630 | 157.5 ± 8.9c |
| 2-AG + AM-251 + AM-630 | 66.5 ± 2.5c |
| 2-AG + Capsa | 138.3 ± 16.4c |
MSCs were pretreated for 1 h with AM-251 (CB1 antagonist), AM-630 (CB2 antagonist), or capsazepine (Capsa) (TRPV1 antagonist) at 1 μM concentrations prior to addition of vehicle, FAAH inhibitors (URB597 and AA-5HT; 10 μM), or endocannabinoids (AEA and 2-AG; 10 μM) and incubation for another 6 h. Percent control represents mean ± SEM compared with vehicle control (100%) of n = 3–4 experiments from one donor.
a
P < 0.05 versus corresponding vehicle.
b
Not significant versus corresponding vehicle.
c
P < 0.05 versus cells treated with the respective FAAH inhibitor or endocannabinoid, one-way ANOVA plus post hoc Bonferroni test.